Q-omics provides the consensus-scored CEP126 profile across patient tissues and cancer cell-line models. CEP126 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, CEP126 is differentially expressed in 15, with the highest sampling consensus in KICH. Additionally, CEP126 RNA expression shows 20,297 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LIHC, KICH, and THYM as cancer lineages where CEP126 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CEP126 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CEP126 survival associations across molecular data types. CEP126 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (6) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CEP126 RNA expression–survival associations across cancer types. High CEP126 expression shows unfavorable associations in LIHC, LUSC, KIRP, LUAD and ESCA, but favorable associations in SKCM. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .006). Together, the overview and detailed table identify LIHC as the clearest survival context for CEP126 RNA expression.
This table summarizes CEP126 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for CEP126. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CEP126 shows lower tumor expression in KICH, THCA, LUSC, BLCA and UCEC and higher tumor expression in KIRC. The KICH box plot shows higher CEP126 RNA expression in normal versus tumor tissue (log2 FC = −1.760, t-test p < 0.001).
This table shows molecular features associated with CEP126 in patient tissues and cancer cell lines. In patient samples, CEP126 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, CEP126 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and CNS.
